NGNE

insider transactions

Neurogene Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-32.0K

0 buy · 32.0K sell

Net value · 365d

-$793.6K

$0 in · $793.6K out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 32.0K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
May 6, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$155.7K

4.8K sh · $32.44

Own -5%
Sell·S
May 6, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$144.4K

4.8K sh · $30.07

Own -5%
Grant·A
May 5, 26

Christina Shafer

Chief Commercial Officer

$0

120.0K sh

Own New
Sell·S
Mar 26, 26

Rachel Mcminn KEY

Chief Executive Officer · 10b5-1

$74.0K

3.4K sh · $22.07

Own -0%
Sell·S
Mar 26, 26

Julie Jordan

Chief Medical Officer · 10b5-1

$18.1K

828 sh · $21.89

Own -6%
Sell·S
Mar 26, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$55.3K

2.6K sh · $21.62

Own -2%
Sell·S
Mar 13, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$5.8K

263 sh · $22.02

Own -0%
Sell·S
Mar 13, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$29.6K

1.4K sh · $21.25

Own -1%
Sell·S
Mar 13, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$48.7K

2.4K sh · $20.42

Own -2%
Sell·S
Mar 13, 26

Stuart Cobb

Chief Scientific Officer · 10b5-1

$3.3K

148 sh · $22.08

Own -0%
Sell·S
Mar 13, 26

Stuart Cobb

Chief Scientific Officer · 10b5-1

$56.7K

2.7K sh · $21.34

Own -8%
Sell·S
Mar 13, 26

Stuart Cobb

Chief Scientific Officer · 10b5-1

$81.5K

4.0K sh · $20.41

Own -11%
Sell·S
Feb 27, 26

Christine Mikail Cvijic KEY

President and CFO · 10b5-1

$120.5K

4.8K sh · $25.11

Own -4%
Grant·A
Feb 20, 26

Keith Woods

Director

$0

12.1K sh

Own New
Grant·A
Feb 20, 26

Sarah B. Noonberg

Director

$0

12.1K sh

Own New
Grant·A
Feb 20, 26

Rohan Palekar

Director

$0

12.1K sh

Own New
Grant·A
Feb 20, 26

Rachel Mcminn KEY

Chief Executive Officer

$0

155.1K sh

Own New
Grant·A
Feb 20, 26

Rachel Mcminn KEY

Chief Executive Officer

$0

25.9K sh

Own +2%
Grant·A
Feb 20, 26

Julie Jordan

Chief Medical Officer

$0

29.6K sh

Own New
Grant·A
Feb 20, 26

Julie Jordan

Chief Medical Officer

$0

4.9K sh

Own +58%
Grant·A
Feb 20, 26

Cory S. Freedland

Director

$0

12.1K sh

Own New
Grant·A
Feb 20, 26

Christine Mikail Cvijic KEY

President and CFO

$0

131.9K sh

Own New
Grant·A
Feb 20, 26

Christine Mikail Cvijic KEY

President and CFO

$0

22.0K sh

Own +24%
Grant·A
Feb 20, 26

Stuart Cobb

Chief Scientific Officer

$0

16.5K sh

Own +79%
Grant·A
Feb 20, 26

Robert Baffi

Director

$0

12.1K sh

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 6, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	4.8K	-5%	$32.44	$155.7K
May 6, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	4.8K	-5%	$30.07	$144.4K
May 5, 2026	Christina Shafer	Chief Commercial Officer	Grant A	120.0K	New	—	$0
Mar 26, 2026	Rachel Mcminn KEY 10b5-1	Chief Executive Officer	Sell S	3.4K	-0%	$22.07	$74.0K
Mar 26, 2026	Julie Jordan 10b5-1	Chief Medical Officer	Sell S	828	-6%	$21.89	$18.1K
Mar 26, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	2.6K	-2%	$21.62	$55.3K
Mar 13, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	263	-0%	$22.02	$5.8K
Mar 13, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	1.4K	-1%	$21.25	$29.6K
Mar 13, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	2.4K	-2%	$20.42	$48.7K
Mar 13, 2026	Stuart Cobb 10b5-1	Chief Scientific Officer	Sell S	148	-0%	$22.08	$3.3K
Mar 13, 2026	Stuart Cobb 10b5-1	Chief Scientific Officer	Sell S	2.7K	-8%	$21.34	$56.7K
Mar 13, 2026	Stuart Cobb 10b5-1	Chief Scientific Officer	Sell S	4.0K	-11%	$20.41	$81.5K
Feb 27, 2026	Christine Mikail Cvijic KEY 10b5-1	President and CFO	Sell S	4.8K	-4%	$25.11	$120.5K
Feb 20, 2026	Keith Woods	Director	Grant A	12.1K	New	—	$0
Feb 20, 2026	Sarah B. Noonberg	Director	Grant A	12.1K	New	—	$0
Feb 20, 2026	Rohan Palekar	Director	Grant A	12.1K	New	—	$0
Feb 20, 2026	Rachel Mcminn KEY	Chief Executive Officer	Grant A	155.1K	New	—	$0
Feb 20, 2026	Rachel Mcminn KEY	Chief Executive Officer	Grant A	25.9K	+2%	—	$0
Feb 20, 2026	Julie Jordan	Chief Medical Officer	Grant A	29.6K	New	—	$0
Feb 20, 2026	Julie Jordan	Chief Medical Officer	Grant A	4.9K	+58%	—	$0
Feb 20, 2026	Cory S. Freedland	Director	Grant A	12.1K	New	—	$0
Feb 20, 2026	Christine Mikail Cvijic KEY	President and CFO	Grant A	131.9K	New	—	$0
Feb 20, 2026	Christine Mikail Cvijic KEY	President and CFO	Grant A	22.0K	+24%	—	$0
Feb 20, 2026	Stuart Cobb	Chief Scientific Officer	Grant A	16.5K	+79%	—	$0
Feb 20, 2026	Robert Baffi	Director	Grant A	12.1K	New	—	$0

About NGNE insider trading

This page tracks insider transactions for Neurogene Inc. (NGNE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.